These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 11559718

  • 1. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M.
    J Clin Oncol; 2001 Sep 15; 19(18):3808-16. PubMed ID: 11559718
    [Abstract] [Full Text] [Related]

  • 2. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
    Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR.
    Cancer Res; 2003 Oct 01; 63(19):6523-31. PubMed ID: 14559846
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
    Lancet Oncol; 2008 Jan 01; 9(1):23-8. PubMed ID: 18083065
    [Abstract] [Full Text] [Related]

  • 4. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.
    J Clin Oncol; 2006 Jul 01; 24(19):3019-25. PubMed ID: 16754938
    [Abstract] [Full Text] [Related]

  • 5. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2007 Sep 01; 25(25):3846-52. PubMed ID: 17679725
    [Abstract] [Full Text] [Related]

  • 6. Anti-tumor effects of letrozole.
    Miller WR, Anderson TJ, Dixon JM.
    Cancer Invest; 2002 Sep 01; 20 Suppl 2():15-21. PubMed ID: 12442345
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W, Deng H, Rao N, You N, Yang Y, Cao M, Liu J.
    Trials; 2017 Oct 25; 18(1):497. PubMed ID: 29070044
    [Abstract] [Full Text] [Related]

  • 8. Letrozole in the neoadjuvant setting: the P024 trial.
    Ellis MJ, Ma C.
    Breast Cancer Res Treat; 2007 Oct 25; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
    [Abstract] [Full Text] [Related]

  • 9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 10. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
    Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group.
    Ann Oncol; 2001 Nov 10; 12(11):1527-32. PubMed ID: 11822750
    [Abstract] [Full Text] [Related]

  • 11. Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria?
    Pritchard KI.
    J Clin Oncol; 2001 Sep 15; 19(18):3795-7. PubMed ID: 11559715
    [No Abstract] [Full Text] [Related]

  • 12. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W.
    J Clin Oncol; 2003 May 15; 21(10):1967-72. PubMed ID: 12743150
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5108-16. PubMed ID: 15998903
    [Abstract] [Full Text] [Related]

  • 14. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Aug 01; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 15. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
    Smith IE.
    J Steroid Biochem Mol Biol; 2003 Sep 01; 86(3-5):289-93. PubMed ID: 14623523
    [Abstract] [Full Text] [Related]

  • 16. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 17. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P.
    J Clin Oncol; 2014 Apr 01; 32(10):1050-7. PubMed ID: 24590635
    [Abstract] [Full Text] [Related]

  • 18. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A, Font López KC, Amador DD.
    Ginecol Obstet Mex; 2011 Sep 01; 79(9):553-7. PubMed ID: 21966856
    [Abstract] [Full Text] [Related]

  • 19. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
    Garimella V, Hussain T, Agarwal V, Radhakrishna S, Fox JN, Kneeshaw PJ, Long ED, Mahapatra TK, McManus PL, Lind MJ, Drew PJ, Cawkwell L.
    Int J Surg; 2014 Sep 01; 12(8):821-6. PubMed ID: 25010604
    [Abstract] [Full Text] [Related]

  • 20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.
    J Clin Oncol; 2009 Nov 20; 27(33):5538-46. PubMed ID: 19786658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.